Pharmaceutical company Galderma has released new research and guidelines on skin care after weight loss medication use.
The research reveals loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with 45% of 1,000 respondents typically observing facial changes three to six months following treatment. Galderma also found more than 60% of patients displayed a strong interest in integrating both medical and aesthetic practices to support their weight loss journey.
Galderma shared that global sales of prescription weight loss drugs are predicted to reach $100 billion by 2030, significantly impacting both patients and healthcare professionals. With 62% of GLP-1 users receiving aesthetic treatments upon professional recommendation, the company emphasises the need for stricter regulation.
Gerry Muhle, head of global product strategy at Galderma, commented, “Galderma is committed to leading the way in understanding the impact of medication-driven weight loss on the skin. With our deep skin knowledge, aesthetic expertise and individualised treatment approach, Galderma is uniquely positioned to support this evolution and help patients achieve the radiant glow and appearance that they desire.” Galderma is exhibiting at ACE 2025 at the Business Design Centre on March 14-15. Turn to p.21 to register free now.
